Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease [Hematologic Malignancy]

Conclusion
Allogeneic anti-CD19 CAR T cells can effectively treat B-cell malignancies that progress after alloHSCT. The findings point toward a future when antigen-specific T-cell therapies will play a central role in alloHSCT.

Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Brudno, Somerville, Shi, Rose, Halverson, Fowler, Gea-Banacloche, Pavletic, Hickstein, Lu, Feldman, Iwamoto, Kurlander, Maric, Goy, Hansen, Wilder, Blacklock-Schuver, Hakim, Rosenberg, Gress, Kochenderfer Tags: Leukemia, Lymphoma, Biologic Therapy, Biological Therapy, Immunology/Immunobiology Hematologic Malignancy Source Type: research